Search
Fencamfamin
go.drugbank.com/drugs/DB01463ApprovedIllicitWithdrawnFencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. It is especially useful in patients with chronic conditions due to its favourable safety profile. … Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant.
Categories: Psychostimulants, Agents Used for ADHD and NootropicsLurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalFood and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. … Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeBenzonatate
go.drugbank.com/drugs/DB00868Approved[L11193] Although it not prone to drug misuse or abuse, benzonatate is associated with a risk for severe toxicity and overdose, especially in children.[A189513] … [A189519] It works to reduce the activity of cough reflex by desensitizing the tissues of the lungs and pleura involved in the cough reflex.
Categories: Non-narcotic AntitussiveSynonyms: nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate, p-butylaminobenzoic acid ω-O-methylnonaethyleneglycol esterBuspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigationalIt has also been used as a second-line therapy for unipolar depression when the use of selective serotonin reuptake inhibitors (SSRIs) is deemed clinically inadequate or inappropriate. … Belonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Co BuspironeFitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigational[L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B. … Fitusiran is an antithrombin-directed double-stranded small interfering ribonucleic acid (siRNA) that is covalently linked to a ligand containing a triantennary N-acetylgalactosamine (GalNAc) moiety.
Metal cation symporter ZIP8
go.drugbank.com/bio_entities/BE0009901TransporterHumansProtects, for instance, cells from injury and death at the onset of inflammation (PubMed:18390834). … Also participates in manganese reabsorption in the proximal tubule of the kidney (PubMed:26637978).
Synonyms: BCG-induced integral membrane protein in monocyte clone 103 proteinMecasermin rinfabate
go.drugbank.com/drugs/DB14751ApprovedInvestigationalMecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH)[A176020]. … In 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency[F4075].
Synonyms: rhIGF-I/rhIGFBP-3, Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3Butalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitThere have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition. … Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully
Synonyms: 5-allyl-5-(2'-methyl-n-propyl) barbituric acidGepirone
go.drugbank.com/drugs/DB12184ApprovedIt was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant. … [A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePegzilarginase
go.drugbank.com/drugs/DB14780ApprovedFDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).
Synonyms: Co-ArgI-PEG modified human arginase I, Optimised human arginase I